Related Experiment Video
Updated: Dec 21, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Long noncoding RNA CCAT1 inhibits miR-613 to promote nonalcoholic fatty liver disease via increasing LXRα
Feizhou Huang1, Huaizheng Liu1, Zhao Lei1
1Emergency Department, The Third Xiangya Hospital, Central South University, Changsha, China.
Abstract:
Nonalcoholic fatty liver disease (NAFLD) is regarded as a threat to public health; however, the pathologic mechanism of NAFLD is not fully understood. We attempted to identify abnormally expressed long noncoding RNA (lncRNAs) and messenger RNA that may affect the occurrence and development of NAFLD in this study. The expression of differentially expressed lncRNAs in NAFLD was determined in oleic acid (OA)-treated L02 cells, and the functions of CCAT1 in lipid droplet formation were evaluated in vitro. Differentially expressed genes (DEGs) were analyzed by microarray analysis, and DEGs related to CCTA1 were selected and verified by weighted correlation network analysis. The dynamic effects of LXRα and CCTA1 on lipid droplet formation and predicted binding was examined. The binding between miR-631 and CCAT1 and LXRα was verified. The dynamic effects of miR-613 inhibition and CCTA1 silencing on lipid droplet formation were examined. The expression and correlations of miR-631, CCAT1, and LXRα were determined in tissue samples. As the results show, CCAT1 was induced by OA and upregulated in NAFLD clinical samples. CCAT1 silencing significantly suppressed lipid droplet accumulation in vitro. LXRα was positively correlated with CCAT1. By inhibiting miR-613, CCAT1 increased the transcription of LXRα and promoted LXRα expression. The expression of LXRα was significantly increased in NAFLD tissues and was positively correlated with CCAT1. In conclusion, CCAT1 increases LXRα transcription by serving as a competing endogenous RNA for miR-613 in an LXRE-dependent manner, thereby promoting lipid droplet formation and NAFLD. CCAT1 and LXRα might be potent targets for NAFLD treatment.
Insights
CCAT1, a long noncoding RNA, promotes lipid droplet formation in nonalcoholic fatty liver disease (NAFLD) by upregulating LXRα. Targeting CCAT1 and LXRα may offer new treatments for NAFLD.
Area of Science:
- Molecular Biology
- Hepatology
- Genetics
Background:
- Nonalcoholic fatty liver disease (NAFLD) is a growing public health concern with incompletely understood pathological mechanisms.
- Long noncoding RNAs (lncRNAs) and messenger RNAs are implicated in NAFLD development, but their specific roles require further elucidation.
Purpose of the Study:
- To identify abnormally expressed lncRNAs and mRNAs involved in NAFLD pathogenesis.
- To investigate the functional role of CCAT1 in lipid droplet accumulation and its regulatory mechanism in NAFLD.
Main Methods:
- Oleic acid (OA)-treated L02 cells were used to assess lncRNA expression and CCAT1 function in vitro.
- Microarray analysis identified differentially expressed genes (DEGs), with CCAT1-related DEGs verified by weighted correlation network analysis.
- Interactions between CCAT1, miR-613, and LXRα were examined, including binding verification and expression analysis in NAFLD tissue samples.
Main Results:
- CCAT1 expression was induced by OA and upregulated in NAFLD clinical samples.
- Silencing CCAT1 significantly reduced lipid droplet accumulation in vitro, indicating its pro-lipogenic role.
- CCAT1 was found to increase LXRα transcription by acting as a competing endogenous RNA for miR-613, thereby promoting LXRα expression and lipid droplet formation.
Conclusions:
- CCAT1 promotes lipid droplet formation and NAFLD progression by upregulating LXRα transcription via the miR-613/CCAT1/LXRα axis.
- CCAT1 and LXRα represent potential therapeutic targets for managing nonalcoholic fatty liver disease.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
MicroRNAs
MicroRNAs
Types of RNA
RNA Performs Diverse...
Inheritance of Chromatin Structures

